Pedro Mezquita-Raya1, Josep Darbà2, Meritxell Ascanio3, Antonio Ramírez de Arellano4. 1. a Hospital Torrecardenas , Clínica San Pedro , Almería , Spain. 2. b Department of Economics , Universitat de Barcelona , Barcelona , Spain. 3. c Department of Health Economics , BCN Health Economics & Outcomes Research S.L ., Barcelona , Spain. 4. d HEOR Europe , Novo Nordisk , Madrid , Spain.
Abstract
BACKGROUND: The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. METHODS: A short-term cost utility model was developed to estimate effectiveness results in terms of the total number of hypoglycaemic events and their disutility impact throughout the year on the initial level of quality of life for patients in each treatment. RESULTS: Degludec was the dominant strategy for T2DM BOT and exhibited an incremental cost-effectiveness ratio of 52.70€/QALY and 11,240.88€/QALY for T1DM B/B and T2DM B/B, respectively. Lower costs are primarily driven by lower nocturnal and severe hypoglycaemic events, which were reduced versus IGlar. Improvements in clinical outcomes in all three patient groups are result of the reduced number of hypoglycaemic events showing 0.0211, 0.0328 and 0.0248 QALYs gained when compared to IGlar for T1DM B/B, T2DM BOT and T2DM B/B, respectively. Different scenario analyses showed that the ICERS were stable to plausible variations in the analysed parameters, except when the same number of SMBG for both treatments is used, with T2DM B/B showing an ICER over the accepted threshold. CONCLUSION: This analysis demonstrates that degludec is a cost-effective option in the Spanish NHS, when used in patients currently treated with long-acting insulin.
BACKGROUND: The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. METHODS: A short-term cost utility model was developed to estimate effectiveness results in terms of the total number of hypoglycaemic events and their disutility impact throughout the year on the initial level of quality of life for patients in each treatment. RESULTS: Degludec was the dominant strategy for T2DM BOT and exhibited an incremental cost-effectiveness ratio of 52.70€/QALY and 11,240.88€/QALY for T1DM B/B and T2DM B/B, respectively. Lower costs are primarily driven by lower nocturnal and severe hypoglycaemic events, which were reduced versus IGlar. Improvements in clinical outcomes in all three patient groups are result of the reduced number of hypoglycaemic events showing 0.0211, 0.0328 and 0.0248 QALYs gained when compared to IGlar for T1DM B/B, T2DM BOT and T2DM B/B, respectively. Different scenario analyses showed that the ICERS were stable to plausible variations in the analysed parameters, except when the same number of SMBG for both treatments is used, with T2DM B/B showing an ICER over the accepted threshold. CONCLUSION: This analysis demonstrates that degludec is a cost-effective option in the Spanish NHS, when used in patients currently treated with long-acting insulin.
Entities:
Keywords:
Diabetes type 1; ICER; costs; diabetes type 2; effectiveness; hypoglycaemic episodes; insulin degludec; insulin glargine
Authors: Richard F Pollock; William J Valentine; Steven P Marso; Andreas Andersen; Jens Gundgaard; Nino Hallén; Deniz Tutkunkardas; Elizabeth A Magnuson; John B Buse Journal: Appl Health Econ Health Policy Date: 2019-10 Impact factor: 2.561
Authors: Richard F Pollock; Simon Heller; Thomas R Pieber; Vincent Woo; Jens Gundgaard; Nino Hallén; Maria Luckevich; Deniz Tutkunkardas; Bernard Zinman Journal: Diabetes Obes Metab Date: 2019-04-14 Impact factor: 6.577